INKmune

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameINKmune
Drug Alias NameINB 16
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesProstatic Neoplasms, Castration-ResistantOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomGreece
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInmune Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesInmune Bio Inc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsMyelodysplastic SyndromesOvarian NeoplasmsLeukemia, Myeloid, Acute +[4] 

Other Information

ATC CodeN/A
Related LinksN/A